Association of Accessible Medicines (Formerly Known as Gpha)

Trade Organization for Generic Drug Manufacturers and Distributers

Based in DC

🤖

AI Overview

With $1.8M in lobbying spend across 32 quarterly filings, Association of Accessible Medicines (Formerly Known as Gpha) is a significant lobbying presence. Their lobbying covers 2 issue areas. Active from 2018 to 2025.

$1.8M
Total Spend
8
Years Active
1
Firms Hired
10
Lobbyists Deployed
2
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$240K
2019$240K
2020$220K
2021$220K
2022$240K
2023$200K
2024$230K
2025$240K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Trade

  • Issues relating to generic drug competition, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, S. 2514- PACED Act
  • Issues relating to generic drug competition, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, S. 2514- PACED Act, Hatch Waxman Integrity Act
  • Issues relating to generic drug competition, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, Hatch Waxman Integrity Act
  • USMCA/NAFTA

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.